Structure Therapeutics Inc. (NASDAQ:GPCR)
| Market Cap | $928.55M-54.3% |
| Revenue (ttm) | n/a |
| Net Income | n/a-39.6% |
| EPS | n/a-7.4% |
| Shares Out | 57.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 786,126 |
| Open | $16.73 |
| Previous Close | $17.12 |
| Day's Range | $16.06 - $17.08 |
| 52-Week Range | $16.06 - $94.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $90.50(+461.07%) |
| Earnings Date | n/a |
About GPCR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Analyst consensus
1 firm rating GPCR in the last 3 months, one vote each. Issuer-paid research is not counted.
$GPCR stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of GPCR by members of U.S. Congress
| Thomas Richard CarperSenate | Sale$1.00K – $15.00K | Oct 4, 2023 |
Recently reported changes in GPCR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GPCR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GPCR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GPCR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GPCR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GPCR
| IBBiShares Biotechnology ETF | $8.23M |
| FDGAmerican Century Focused Dynamic Growth ETF | $1.62M |
| FSMOFidelity Fundamental Small-Mid Cap ETF | $1.47M |
| FFSMFidelity Fundamental Small-Mid Cap ETF | $1.47M |
| SPEMState Street SPDR Portfolio Emerging Markets ETF | $1.43M |
| SBIOALPS Medical Breakthroughs ETF | $1.41M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GPCR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Morgan Stanley maintained Outperform with modest PT cut; wider losses offset by business collaboration and operational highlights reported.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| THNR | Amplify Weight Loss Drug & Treatment ETF | 2.02% |
| LRNZ | TrueShares Technology, AI and Deep Learning ETF | 1.83% |
| OZEM | Roundhill Investments - GLP-1 & Weight Loss ETF | 1.54% |
| WDNA | WisdomTree BioRevolution Fund | 1.05% |
| MID | American Century Mid Cap Growth Impact ETF | 0.95% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.93% |
| FDG | American Century Focused Dynamic Growth ETF | 0.38% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.36% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.10% |
| FSMO | Fidelity Fundamental Small-Mid Cap ETF | 0.10% |
| FFSM | Fidelity Fundamental Small-Mid Cap ETF | 0.10% |
| IBB | iShares Biotechnology ETF | 0.08% |
Weight is the stock’s share of each fund’s holdings.
